COMMONS

Genomics and genome editing in the NHS examined

26 October 2017

The Science and Technology Committee inquiry into ‘genomics and genome editing in the NHS’ carries forward the previous Committee’s inquiry into ‘genomics and genome editing’. This session aims to focus on issues arising from the Chief Medical Officer’s annual report and the Life Science Industrial Strategy, both published this summer

Witnesses

Wednesday 1 November 2017, Committee Room 6, Palace of Westminster

At 2.30pm

  • Dr Magdalini Papadaki, Head of Product and Process Innovation, Association of the British Pharmaceutical Industry
  • Professor Sir John Bell, Regius Professor of Medicine, University of Oxford

At 3.30 pm

  • Dr Mark Kroese, Chair, Diagnostics Advisory Committee, National Institute for Health and Care Excellence
  • Professor Sue Hill, Chief Scientific Officer for England, NHS England
  • Professor William Newman, Vice Chair, British Society for Genetic Medicine

Purpose of the session

The first panel will discuss the CMO’s report and the Life Sciences Industrial Strategy from industry’s point of view. It will review the potential for genomics and genome editing, NHS engagement with industry and regulatory challenges.

The second panel will examine current plans and potential challenges involved in making genomics a routine part of NHS care and realising the Chief Medical Officer’s ‘genomic dream’. It will aim to evaluate evidence from the 100,000 Genomes Project, and cover patient welfare, costs, infrastructure and NHS workforce skills going forward.

Further information

Image: CC0 Creative Commons

More news on: Parliament, government and politics, Science and technology, Science, Parliament, House of Commons news, Commons news, Committee news, Genetics

Share this page